CN114901290B - 抑制血管新生因子的化合物及其用途 - Google Patents

抑制血管新生因子的化合物及其用途 Download PDF

Info

Publication number
CN114901290B
CN114901290B CN202080090674.9A CN202080090674A CN114901290B CN 114901290 B CN114901290 B CN 114901290B CN 202080090674 A CN202080090674 A CN 202080090674A CN 114901290 B CN114901290 B CN 114901290B
Authority
CN
China
Prior art keywords
chemical formula
compound
angiogenic
case
trap1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080090674.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114901290A (zh
Inventor
姜秉宪
金昭延
尹南球
李昌昱
朴东浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smartbio
UNIST Academy Industry Research Corp
Original Assignee
Smartbio
UNIST Academy Industry Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartbio, UNIST Academy Industry Research Corp filed Critical Smartbio
Publication of CN114901290A publication Critical patent/CN114901290A/zh
Application granted granted Critical
Publication of CN114901290B publication Critical patent/CN114901290B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080090674.9A 2019-12-16 2020-12-16 抑制血管新生因子的化合物及其用途 Active CN114901290B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0168238 2019-12-16
KR20190168238 2019-12-16
PCT/KR2020/018475 WO2021125800A1 (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Publications (2)

Publication Number Publication Date
CN114901290A CN114901290A (zh) 2022-08-12
CN114901290B true CN114901290B (zh) 2024-09-03

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090674.9A Active CN114901290B (zh) 2019-12-16 2020-12-16 抑制血管新生因子的化合物及其用途

Country Status (9)

Country Link
US (1) US12545695B2 (https=)
EP (1) EP4079309A4 (https=)
JP (1) JP7831775B2 (https=)
KR (1) KR20210076875A (https=)
CN (1) CN114901290B (https=)
AU (1) AU2020409912A1 (https=)
BR (1) BR112022011147A2 (https=)
CA (1) CA3164800A1 (https=)
WO (1) WO2021125800A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Ｔｒａｐ１阻害剤およびその用途
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102438615A (zh) * 2009-04-17 2012-05-02 科尔比制药公司 包含氧化应激调节剂(osm)的药学活性组合物、新的化学实体、组合物和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102438615A (zh) * 2009-04-17 2012-05-02 科尔比制药公司 包含氧化应激调节剂(osm)的药学活性组合物、新的化学实体、组合物和用途

Also Published As

Publication number Publication date
WO2021125800A1 (ko) 2021-06-24
AU2020409912A1 (en) 2022-06-16
JP7831775B2 (ja) 2026-03-17
EP4079309A1 (en) 2022-10-26
CN114901290A (zh) 2022-08-12
US12545695B2 (en) 2026-02-10
KR20210076875A (ko) 2021-06-24
CA3164800A1 (en) 2021-06-24
US20230088747A1 (en) 2023-03-23
EP4079309A4 (en) 2024-01-10
JP2023506838A (ja) 2023-02-20
BR112022011147A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
AU2021201332B2 (en) Compositions and methods of modulating short-chain dehydrogenase activity
CN114901290B (zh) 抑制血管新生因子的化合物及其用途
EP3215155A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
CN104334543B (zh) 抗新生血管的化合物、其中间体及其用途
TW200940549A (en) Inhibitors of protein tyrosine kinase activity
US20200268736A1 (en) Compositions and methods for treating inflammatory bowel disease
CN109862893A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2019178383A1 (en) Inhibition of bmp signaling, compounds, compositions and uses thereof
CN114390924B (zh) 用于蛋白质降解的化合物、组合物和方法
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
WO2014158302A1 (en) Novel sphingosine 1-phosphate receptor antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant